New chemotherapy strategies and biological agents in the treatment of childhood ependymoma

Child's Nervous System

Volumn 25, Issue 10, 2009, Pages 1275-1282

  Wright, Karen D ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Brain tumor; Ependymoma; Therapy; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ERLOTINIB; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; SORAFINIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; DNA DAMAGE; EPENDYMOMA; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; HUMANS; INFANT; QUINAZOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69949133709     PISSN: 02567040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00381-009-0809-7     Document Type: Review

References (83)

1. Strother DR, Pollack IF, Fisher PG, Hunter JV, Woo SY, Pomeroy SL, Rorke LB (2003) Tumors of the central nervous system. In: Pizzo P, Poplack D (eds) Priniciples and practice of pediatric oncology, 4th edn. Lippincott Williams & Wilkins, New York, pp 778-785
2. NK Foreman S Love R Thorne 1996 Intracranial ependymomas: analysis of prognostic factors in a population-based series Pediatr Neurosurg 24 119 125
3. G Perilongo M Massimino G Sotti T Belfontail L Masiero L Rigobello L Garre M Carli F Lomabardi C Solero L Sainati V Canale AB del Prever F Giangaspero L Andreussi C Mazza E Madon 1997 Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-Oncology Group Med Pediatr Oncol 29 79 85
4. B Horn R Heideman R Geyer I Pollack R Packer J Goldwein T Tomita J Schomberg Ater L Luchtman-Jones K Rivlin K Lamborn M Pradose A Bollen M Berger E Dahl McNeil K Patterson D Shaw M Kubalik C Russo 1999 A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors J Pediatr Hematol Oncol 21 203 211
5. LN Sutton J Goldwein G Perilongo B Lang L Schut L Rorke R Packer 1990 Prognostic factors in childhood ependymomas Pediatr Neurosurg 16 57 65
6. AE Evans JR Anderson IB Lefkowitz-Boudreaux JL Finlay 1996 Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study Med Pediatr Oncol 27 8 14
7. Mclendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM (1988) Tumors of central epithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's pathology of tumors of the nervous system. Arnold, London, pp 387-418
8. PL Robertson PM Zeltzer JM Boyett LB Rorke JC Allen JR Geyer P Stanley H Li AL Albright P [tmp] McGuire-Cullen JL Finlay KR Stevens Jr JM Milstein RJ Packer J Wisoff 1998 Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group J Neurosurg 88 695 703 (Pubitemid 28145213)
9. IF Pollack PC Gerszten AJ Martinez KH Lo B Shultz AL Albright J Janosky M Deutsch 1995 Intracranial ependymoma of childhood: long-term outcome and prognostic factors Neurosurgery 37 655 667
10. MN Needle JW Goldwein J Grass A Cnaan I Bergman P Molloy L Sutton H Zhao JK Garvin Jr PC Phillips 1997 Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood Cancer 80 341 347
11. S Zacharoulis Ji Lingyun IF Pollack P Duffner R Geyer J Grill S Schild TH Jaing M Massimino J Finlay R Sposto 2008 Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors Pediatr Blood Cancer 50 231 235
12. JR Geyer PM Zeltzer JM Boyett LB Rorke P Stanley AL Albright JH Wisoff JM Milstein JC Allen Finlay 1994 Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group J Clin Oncol 12 1607 1615
13. N Oya Y Shibamoto Y Nagata Y Negoro Hiraoka 2002 Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure J Neurooncol 56 87 94
14. TE Merchant RK Mulhern MJ Krasin LE Kun T Williams C Li X Xiong RB Khan RH Lustig FA Boop RA Sanford 2004 Preliminary results from a phase II trial of conformal radiaition therapy and evaluation of radiation-related CNS effects of pediatric patients with localized ependymoma J Clin Oncol 22 3156 3162
15. AB Khan BJ D'Souza MD Wharam LA Champion LF Sinks SY Woo DC McCullough BG Leventhal 1982 Cisplatin therapy in recurrent childhood brain tumors Cancer Treat Rep 66 2013 2020
16. CL Sexauer A Khan PC Burger JP Krischer J van Eys T Vats AH Ragab 1985 Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study Cancer 56 1497 1501
17. RW Walker JC Allen 1988 Cisplatin in the treatment of recurrent childhood primary brian tumors J Clin Oncol 6 62 66
18. PS Gaynon LJ Ettinger ES Baum SE Siegel MD Krailo GD Hammond 1990 Carboplatin in childhood brain tumors. A children's cancer study group phase II trial Cancer 66 2465 2469
19. HS Friedman JP Krischer P Burger WJ Oakes B Hockenberger MD Weiner JM Falletta D Norris AH Ragab DH Mahoney Jr 1992 Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a pediatric oncology group randomized phase II study J Clin Oncol 10 249 256
20. P Chastagner D Sommelet-Olive C Kalifa M Brunat-Mentigny JM Zucker F Demeocq MC Baranzelli P Tron C Bergeron F Pein 1993 Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP) Med Pediatr Oncol 21 29 53
21. MN Needle PT Molloy JR Geyer A Herman-Liu JB Belasco JW Goldwein L Sutton PC Phillips 1997 Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors Med Pediatr Oncol 29 28 32
22. A Sandri M Massimino L Mastrodicasa N Sardi D Bertin ME Basso L Todisco A Paglino G Perilongo L Genitori L Valentini U Ricardi L Gandola F Giangaspero E Madon 2005 Treatment with oral etoposide for childhood recurrent ependymomas J Pediatr Hem Oncol 27 286 290
23. HS Nicholson CS Kretschmar M Krailo M Bernstein R Kadota D Fort H Friedman MB Harris N Tedeschi-Blok C Mazewski J Sato GGH Reaman 2007 Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group Cancer 110 1542 1550
24. B Timmermann RD Kortmann J Kuhl C Meisner I Slavc T Pietsch M Bamberg 2000 Combined postoperative irradiation and chemotherapy for anaplastic ependymoma in childhood: results of the German prospective trials HIT 88/89 and HIT 91 Int J Radiat Oncol Biol Phys 46 287 295
25. PK Duffner ME Horowitz JP Krischer HS Friedman PC Burger ME Cohen RA Sanford RK Mulhern HE James CR Freeman 1993 Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors N Engl J Med 328 1725 1731
26. J Grill MC Le Deley D Gambarelli MA Raquin D Couanet A Pierre-Kahn JL Habrand F Doz D Frappaz JC Gentet C Edan P Chastagner C Kalifa French Society of Pediatric Oncology 2001 Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology J Clin Oncol 19 1288 1296
27. L White S Kellie E Gray I Toogood K Waters L Lockwood S Macfarlane H Johnston 1998 Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen J Pediatr Hematology/Oncology 20 125 130
28. JL Ater J van Eys SY Woo B Moore 3rd DR Copeland J Bruner 1997 MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children J Neurooncol 32 243 252
29. S Zacharoulis A Levy SN Chi S Gardner M Rosenblum DC Miller I Dunkel B Diez R Sposto L Ji S Asgharzadeh J Hukin J Belasco R Dubowy S Kellie A Termuhlen J Finlay 2007 Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue Pediatr Blood Cancer 49 34 40
30. J Garvin R Sposto P Stanley L Rorke RJ Packer 2004 Childhood Ependymoma: improved survival for patients with incompletely resected tumors with the use of pre-irradiation chemotherapy Neuro Oncol 6 456
31. HK Shu WF Sall A Maity ZA Tochner AJ Janss JB Belasco LB Rorke-Adams PC Phillips LN Sutton MJ Fisher 2007 Childhood intracranial ependymoma: twenty-year experience from a single institution Cancer 110 432 441
32. GB Nazar HJ Hoffman LE Becker D Jenkin RP Hymphreys EB Hendrick 1990 Infratentorial ependymoma in childhood: prognostic factors and treatment J Neurosurg 72 408 417
33. JK Chiu SY Woo J Ater J Connelly JM Bruner MH Maor J van Eys MJ Oswald R Shallenberger 1992 Intracranial ependymoma in children: analysis of prognostic factors J Neuroonc 13 283 290
34. MN Needle JW Goldwein J Grass A Cnaan I Bergman P Molloy L Sutton H Zhao JH Garvin Jr PC Phillips 1997 Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood Cancer 80 341 347
35. NK Foreman S Love SS Gill HB Coakham 1997 Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report Neurosurgery 40 856 860
36. RS Kerbel BA Kamen 2004 The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 423 436
37. RS Kerbel A Viloria-Petit G Klement J Rak 2000 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples Eur J Cancer 36 1248 1257
38. A Vacca M Iurlaro D Ribatti M Minischetti B Nico R Ria A Pellegrino F Dammacco 1999 Antiangiogenesis is produced by nontoxic doses of vinblastine Blood 94 4143 4155
39. D Hanahan G Bergers E Bergsland 2000 Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105 1045 1047
40. T Browder CE Butterfield BM Kraling B Shi B Marshall MS O'Reilly J Folkman 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886
41. M Colleoni A Rocca MT Sandri L Zorzino G Masci F Nole G Peruzzotti C Robertson L Orlando S Cinieri BF de G Viale A Goldirsch 2002 Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 73 80
42. R Sorio G Toffoli D Crivellari A Bearz G Corona AM Colussi M Libra R Talamini A Veronesi 2006 Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study J Chemother 18 188 191
43. R Buckstein RS Kerbel Y Sheked R Nayar C Foden R Turner CR Lee D Taylor L Zhang S Man S Baruchel D Stempak F Bertolini M Crump 2006 High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma Clin Cancer Res 12 5190 5198
44. K Spieth R Kaufmann J Gille 2003 Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study Cancer Chemother Pharmacol 52 377 382
45. LM Glode A Barqawi F Crighton ED Crawford R Kerbel 2003 Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma Cancer 98 1643 1648
46. S Baruchel M Diezi D Hargrave D Stempak J Gammon A Moghrabi MJ Coppes CV Fernandez E Bouffet 2006 Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumors Eur J Cancer 42 2335 2342
47. D Stempak J Gammon J Halton A Moghrabi G Koren S Baruchel 2006 A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors J Pediatr Hematol Oncol 28 720 728
48. MW Kieran CD Turner JB Rubin SN Chi MA Zimmerman C Chordas G Klement A Laforme A Gordon A Thomas D Neuberg T Browder J Folkman 2005 A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer J Pediatr Hematol Oncol 27 573 581
49. C Khanna LJ Helman 2006 Molecular approaches in pediatric oncology Annual Review of Medicine 57 83 97
50. RS Kerbel 2006 Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312 1171 1175
51. MK Nyati MA Morgan TS Lawrence 2006 Integration of EGFR inhibitors with radiochemotherapy Nat Rev Cancer 6 876 885
52. RJ Gilbertson E Jaros RH Perry PJ Kelly J Lunec AD Pearson 1997 Mitotic percentage index: a new prognostic factor for childhood medulloblastoma Eur J Cancer 33 609 615
53. RJ Gilbertson SC Clifford W [tmp] MacMeekin W Meeken C Wright RH Perry P Kelly AD Pearson J Lunec 1998 Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma Cancer Res 58 3932 3941
54. R Gilbertson C Wickramasinghe R Hernan V Balaji D Hunt D Jones-Wallace J Crolla R Perry J Lunec A Pearson D Ellison 2001 Clinical and molecular stratification of disease risk in medulloblastoma Br J Cancer 85 705 712
55. R Hernan R Fasheh C Calabrese AJ Frank KH Maclean D Allard R Baccaclough RJ Gilbertson 2003 ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastomas Cancer Res 63 140 148
56. RJ Gilbertson L Bentley R Hernan TT Junttila AJ Frank H Haapasalo M Connelly C Wetmore T Curran K Elenius DW Ellison 2002 ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease Clin Cancer Res 8 3054 3064
57. F Medrzyk A Korshunov A Benner G Toedt S Pfister B Radlwimmer P Lichter 2006 Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma Clin Cancer Res 12 2070 2079
58. FM Sirotnak 2003 Studies with ZD1839 in preclinical models Semin Oncol 30 12 20
59. MH Cohen GA Williams R Sridhara G Chen WD [tmp] McGuinn Jr D Morse S Abraham A Rahman C Liang R Lostritto A Baird R Pazdur 2004 United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 1212 1218
60. JS Ochs 2004 Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors Int J Radiat Oncol Biol Phys 58 941 949
61. B Geoerger N Gaspar P Opolon J Morizet P Devanz Y Lecluse A Valent L Lacroix J Grill G Vassal 2008 EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts Int J Cancer 123 209 216
62. MD Taylor H Poppleton C Fuller X Su Y Liu P Jensen S Magdaleno J Dalton C Calabrese J Board T Macdonald J Rutka A Guha A Gajjar T Curran RJ Gilbertson 2005 Radial glia cells are candidate stem cells of ependymoma Cancer Cell 8 323 335
63. A Broniscer JC Panetta M O'Shaughnessy C Fraga F Bai MJ Krasin A Gajjar CF Stewart 2007 Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 Clin Cancer Res 13 1511 1515
64. C Calabrese H Poppleton M Kocak TL Hogg C Fuller B Hamner EY Oh MW Gaber D Finkelstein M Allen A Frank Bayazitov SS Zakharenko A Gajjar A Davidoff RJ Gilbertson 2007 A perivascular niche for brain tumor stem cells Cancer Cell 11 69 82
65. RI Jakacki M Hamilton RJ Gilbertson SM Blany J Tersak MD Krailo AM Ingle SD Voss JE Dancey PC Adamson 2008 Pediatric phase I and pharmokinetic study of erlotinib followed by the combination of erlotinib and temozolamide: a Children's Oncology Group Phase I Consortium Study J Clin Oncol 26 4921 4927
66. P Beaudry M Nilsson M Rioth D Prox D Poon L Xu P Zweidler-Mckay A Ryan J Folkman S Ryeom J Heymach 2008 Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium Mol Cancer Ther 7 418 424
67. A Broniscer SJ Baker CF Stewart TE Merchant FH Laningham P Shaiquevich M Kocak B Morris R Endersby DW Ellison A Gajjar 2009 Phase I and Pharmacokinetic studies of Erlotinib administered concurrently with radiotherapy for children, adolescents and young adults with high-grade glioma Clin Cancer Res 15 701 707
68. RS Kerbel 2001 Clinical trials of antiangiogenic drugs: opportunities, problems and assessment of initial results J Clin Oncol 19 45S 51S
69. R Kerbel J Folkman 2002 Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2 727 739
70. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974
71. G Bergers LE Benjamin 2003 Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 401 410
72. G Bergers S Song 2005 The role of pericytes in blood-vessel formation and maintenance Neuro-onc 7 452 464
73. RS Kerbel 2000 Tumor angiogenesis: past, present and the near future Carcinogenesis 21 505 515
74. S Bao Q Wu S Sathornsumetee Y Hao Z Li AB Hjelmeland Q Shi RE [tmp] McLendon DD Bigner JN Rich 2006 Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 7843 7848
75. B Escudier J Cosaert P Pisa 2008 Bevacizumab: dirent anti-VEGF therapy in renal cell carcinoma Expert Rev Anticancer Ther 8 1545 1557
76. NJ Vogelzang 2006 Treatment options in metastatic renal carcinoma: an embarrassment of riches J Clin Oncol 24 1 3
77. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Homgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Eng J Med 350 2335 2342
78. RK Jain DG Duda JW Clark JS Loeffler 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40
79. JJ Vredenburgh A Desjardins JE Herndon 2nd JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259
80. P Modena E Lualdi F Facchinetti 2006 Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics J Clin Oncol 24 5223 5233
81. U Tabori J Ma M Carter M Zielenska J Rutka E Bouffet U Bartels D Malkin C Hawkins 2006 Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma J Clin Oncol 24 1522 1528
82. S Dyer E Prebble V Davison P Davies P Ramani D Ellison R Grundy 2002 Genomic imbalances in pediatric ependymomas define clinically relevant groups Am J Pathol 161 2133 2141
83. A Korshunov K Neben G Wrobel B Tews A Benner M Hahn A Golanov P Lichter 2003 Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age Am J Pathol 163 1721 1727